INDACATEROL FUMARATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H28N2O3.C4H4O4
Molecular Weight	508.5629
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)\C=C\C(O)=O.CCC1=CC2=C(CC(C2)NC[C@H](O)C3=CC=C(O)C4=C3C=CC(=O)N4)C=C1CC

InChI

InChIKey=IREJFXIHXRZFER-XRQUGHPZSA-N

InChI=1S/C24H28N2O3.C4H4O4/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24;5-3(6)1-2-4(7)8/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29);1-2H,(H,5,6)(H,7,8)/b;2-1+/t22-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C24H28N2O3
Molecular Weight	392.4907
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C4H4O4
Molecular Weight	116.0722
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022383s002lbl.pdf

Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez Breezhaler on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Beta-2 adrenergic receptor 202 Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20402514	Agonist 2637	76.0 nM [Ki]
Beta-1 adrenergic receptor 158 Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20655218	Agonist 2637	91.4 nM [Ki]
Beta-2 adrenergic receptor 202 Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20402514	Agonist 2637	76.0 nM [Ki]
Beta-1 adrenergic receptor 158 Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20655218	Agonist 2637	91.4 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022383s002lbl.pdf	Primary		Approved 8307	ARCAPTA NEOHALER Approved Use UTIBRONTM NEOHALER® is a combination of indacaterol and glycopyrrolate indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Important Limitations of Use: UTIBRON NEOHALER is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions (5.1, 5.2) Launch Date 1.30947835E12
Airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022383s002lbl.pdf	Primary		Approved 8307	ARCAPTA Approved Use INDICATIONS AND USAGE. ARCAPTA NEOHALER is a long-acting beta2-adrenergic agonist indicated for: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Important limitations: ARCAPTA NEOHALER is NOT indicated to treat acute deteriorations of chronic obstructive pulmonary disease. ARCAPTA NEOHALER is NOT indicated for asthma. Launch Date 1.29427204E12

C_max

Value	Dose	Co-administered	Analyte	Population
528 pg/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207930Orig1s000ClinPharmR.pdf	110 μg 1 times / day steady-state, respiratory dose: 110 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: GLYCOPYRROLATE	GLYCOPYRROLATE	INDACATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
339 pg/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207930Orig1s000ClinPharmR.pdf	110 μg single, respiratory dose: 110 μg route of administration: Respiratory experiment type: SINGLE co-administered: GLYCOPYRROLATE	GLYCOPYRROLATE	INDACATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.206 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	150 μg single, respiratory dose: 150 μg route of administration: Respiratory experiment type: SINGLE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.518 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	300 μg single, respiratory dose: 300 μg route of administration: Respiratory experiment type: SINGLE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.299 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	150 μg 1 times / day steady-state, respiratory dose: 150 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.697 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	300 μg 1 times / day steady-state, respiratory dose: 300 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
2750 pg × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207930Orig1s000ClinPharmR.pdf	110 μg 1 times / day steady-state, respiratory dose: 110 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: GLYCOPYRROLATE	GLYCOPYRROLATE	INDACATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
907 pg × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207930Orig1s000ClinPharmR.pdf	110 μg single, respiratory dose: 110 μg route of administration: Respiratory experiment type: SINGLE co-administered: GLYCOPYRROLATE	GLYCOPYRROLATE	INDACATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.974 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	150 μg single, respiratory dose: 150 μg route of administration: Respiratory experiment type: SINGLE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.43 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	300 μg single, respiratory dose: 300 μg route of administration: Respiratory experiment type: SINGLE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.51 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	150 μg 1 times / day steady-state, respiratory dose: 150 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.52 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	300 μg 1 times / day steady-state, respiratory dose: 300 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
116 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	150 μg 1 times / day steady-state, respiratory dose: 150 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
118 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/	300 μg 1 times / day steady-state, respiratory dose: 300 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:		INDACATEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18219838	unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/18219838	Disc. AE: Dyspnea, Wheezing... AEs leading to discontinuation/dose reduction: Dyspnea (serious, 1 patient) Wheezing (serious, 1 patient) Asthma (moderate, 1 patient) Cough (moderate, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/18219838
75 ug 1 times / day multiple, respiratory Dose: 75 ug, 1 times / day Route: respiratory Route: multiple Dose: 75 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022383s000lbl.pdf	unhealthy Health Status: unhealthy Condition: asthma Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022383s000lbl.pdf	Other AEs: Adverse event... Other AEs: Adverse event (grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022383s000lbl.pdf

AEs

AE	Significance	Dose	Population
Asthma	moderate, 1 patient Disc. AE	800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18219838	unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/18219838
Cough	moderate, 1 patient Disc. AE	800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18219838	unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/18219838
Dyspnea	serious, 1 patient Disc. AE	800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18219838	unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/18219838
Wheezing	serious, 1 patient Disc. AE	800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18219838	unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/18219838
Adverse event	grade 5	75 ug 1 times / day multiple, respiratory Dose: 75 ug, 1 times / day Route: respiratory Route: multiple Dose: 75 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022383s000lbl.pdf	unhealthy Health Status: unhealthy Condition: asthma Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022383s000lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1670	substrate 985 inhibitor 1695	substrate 1168 inhibitor 1789	inhibitor 1570

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2E1 846 CYP3A4/5 261 CYP1A2 1463 CYP2C8 869 CYP2C19 1410 P-gp 1401 MRP2 363 BCRP 678 hOCT1 10	UGT1A1 417 UGT1A3 421 UGT1A4 345 UGT1A6 306 UGT1A8 282 UGT1A9 378 UGT1A10 289 UGT2B7 387 UGT2B15 202 CYP1A1 344 CYP1A2 1013 CYP1B1 90 CYP2A6 510 CYP2B6 648 CYP2C8 670 CYP2C18 138 CYP2C19 955 CYP2E1 633 CYP3A5 383 CYP4A11 100 P-gp 1491	P-gp 252 MRP2 108

Drug as perpetrator

Target	Modality	Activity
MRP2 452	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=23 Page: 23.0	negligible
P-gp 1588	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=23 Page: 23.0	negligible
CYP2C9 1747	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	no
CYP2E1 929	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	no
CYP3A4/5 314	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	no
BCRP 751	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=23 Page: 23.0	unlikely
MRP2 452	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=23 Page: 23.0	unlikely
P-gp 1588	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=23 Page: 23.0	unlikely
hOCT1 10	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=23 Page: 23.0	unlikely
CYP1A2 1620	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	weak [IC50 10 uM]
CYP2C19 1484	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	weak [IC50 25 uM]
CYP2C8 923	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	weak [IC50 25 uM]
CYP2D6 1826	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	weak [IC50 5 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A5 383	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=98 Page: 98.0	likely
CYP1A1 344	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	low
CYP2D6 1168	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	low
CYP1A2 1013	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP1B1 90	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP2A6 510	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP2B6 648	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP2C18 138	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP2C19 955	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP2C8 670	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP2C9 985	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP2E1 633	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
CYP4A11 100	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT1A10 289	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT1A3 421	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT1A4 345	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT1A6 306	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT1A8 282	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT1A9 378	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT2B15 202	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
UGT2B7 387	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	no
P-gp 1491	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0	weak	yes (co-administration study) Comment: Co-administration of indacaterol with verapamil (P-gp inhibitor) showed 2 fold increase in indacaterol AUC0-24, and 1.5-fold increase in indacaterol Cmax; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=96 Page: 96.0
UGT1A1 417	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	yes	weak (pharmacogenomic study) Comment: Nonsignificant trends toward higher Cmax and AUC0-24 (19% and 20%, respectively) were noted in patients with the (TA)7 genotype Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0
CYP3A4 1670	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0	yes	yes (co-administration study) Comment: Co-administration of indacaterol with erythromycin (CYP3A4 inhibitor) showed a 1.4-fold increase in indacaterol AUC0-24, and 1.2-fold increase in indacaterol Cmax; Co-administration of indacaterol with ketoconazole caused a 1.9-fold increase in indacaterol AUC0-24, and 1.3-fold increase in indacaterol Cmax; Co-administration of indacaterol with ritonavir resulted in a 1.7-fold increase in indacaterol AUC0-24 whereas indacaterol Cmax was unaffected. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf#page=91 Page: 91.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1603	inhibitor 1584 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000PharmR.pdf#page=46 Page: 46.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:68575	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:68575
ChemicalBook	CB72566367	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB72566367
ChemicalBook	CB82512068	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB82512068
MolPort	MolPort-023-219-171	https://www.molport.com/shop/molecule-link/MolPort-023-219-171
ZINC	ZINC000035801098	http://zinc15.docking.org/substances/ZINC000035801098

PubMed

Title	Date	PubMed
Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease.	2005 Jul	16022567
In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.	2006 May	16434564
Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study.	2007 Dec	18219838
Gateways to clinical trials.	2007 Dec	18200333
Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma.	2007 Dec	17999782
New approaches to managing asthma: a US perspective.	2008 Apr	18728834
Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study.	2008 Jan	18053019
Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices.	2008 Jan	17916760
Gateways to clinical trials.	2008 May	18773127
Gateways to clinical trials.	2009 Apr	19536362
Bronchodilator effects of indacaterol and formoterol in patients with COPD.	2009 Dec	19465142
Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases.	2009 Jul	19609496
24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol.	2009 Oct	19650753
Gateways to clinical trials.	2009 Sep	19907722
[Efficacy and safety of indacaterol - new long-acting beta(2) agonist].	2010	20461692
Impact of bronchodilator therapy on exercise tolerance in COPD.	2010 Apr 7	20463947
Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.	2010 Dec	21166630
Indacaterol for chronic obstructive pulmonary disease (COPD).	2010 Mar	20467588
The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.	2010 Mar	20411368
Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.	2010 Oct 5	20920365
Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone.	2010 Sep 7	20856830
An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol.	2012 Oct 1	22932315

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dosage of Indacaterol is the once-daily inhalation of the contents of one 75 mcg Indacaterol capsule using the NEOHALER inhaler.

Route of Administration: Respiratory

In Vitro Use Guide

In the isolated tracheal strip preparation, indacaterol, demonstrated concentration-dependent inhibition of electrically induced contraction (EC50= 45 ± 13 nM)

Substance Class	Chemical Created by `admin` on `Sun Dec 18 15:28:23 UTC 2022` Edited by `admin` on `Sun Dec 18 15:28:23 UTC 2022`
Record UNII	J3BI9P40XE
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

INDACATEROL FUMARATE

Common Name

English

2(1H)-QUINOLINONE, 5-((1R)-2-((5,6-DIETHYL-2,3-DIHYDRO-1H-INDEN-2-YL)AMINO)-1-HYDROXYETHYL)-8-HYDROXY-, (2E)-2-BUTENEDIOATE (1:1)

Common Name

English

Code System Code Type Description

PUBCHEM

10255695

Created by admin on Sun Dec 18 15:28:23 UTC 2022 , Edited by admin on Sun Dec 18 15:28:23 UTC 2022

PRIMARY

CAS

1000160-87-1

Created by admin on Sun Dec 18 15:28:23 UTC 2022 , Edited by admin on Sun Dec 18 15:28:23 UTC 2022

PRIMARY

FDA UNII

J3BI9P40XE

Created by admin on Sun Dec 18 15:28:23 UTC 2022 , Edited by admin on Sun Dec 18 15:28:23 UTC 2022

PRIMARY

Related Record Type Details


					8OR09251MQ

INDACATEROL

PARENT -> SALT/SOLVATE

Related Record Type Details


					8OR09251MQ

INDACATEROL

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022383s002lbl.pdf

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022383s002lbl.pdf

C_max

T_1/2

Drug as perpetrator